ARTICLE | Strategy
Sourcing biologics in China
Why Lilly went back for second biologics deal with China's Innovent
October 19, 2015 7:00 AM UTC
Eli Lilly and Co.'s decision to go back for seconds with Chinese biotech Innovent Biologics Inc. illustrates a turning tide in a country not historically known for either innovative biologics or manufacturing quality.
Last week the companies partnered to co-develop three bispecific antibodies that build on a preclinical anti-PD-1 mAb from Innovent, IBI308. The deal comes about six months after the companies first partnered to co-develop IBI308 and three other biologics. ...